Ipamorelin + Egrifta (Tesamorelin) Stack: Complete Protocol

Why Combine a GHRH Analog with a GHRP?

Stacking a growth-hormone-releasing hormone analog like tesamorelin with a growth-hormone-releasing peptide like ipamorelin makes physiological sense because the two drugs act at completely different receptors. Short answer: the combination can amplify GH pulse amplitude beyond what either compound achieves alone.

Two Receptors, One Pituitary Target

Tesamorelin binds the GHRH receptor (GHRHR) on pituitary somatotrophs, mimicking the natural hypothalamic signal that tells those cells to synthesize and release GH. Ipamorelin binds the ghrelin receptor (GHSR-1a) on the same somatotrophs and in the hypothalamus, triggering GH release through a distinct intracellular pathway and simultaneously suppressing somatostatin, the GH-inhibitory hormone. [1]

Because the two signals converge on the same effector cell via non-overlapping second-messenger cascades, they can act additively or even synergistically. Animal studies using combined GHRH plus GHRP administration have consistently shown GH responses substantially larger than the sum of either compound's individual effect. [2]

What the Phase III Tesamorelin Data Show

The IGLOO trials (two identically designed 26-week Phase III RCTs, combined N=816 HIV-infected adults with lipodystrophy) established tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 18% (approximately 37 cm²) vs. Placebo, and raised IGF-1 by roughly 80 ng/mL (P<0.001). [3] A 26-week extension confirmed partial VAT rebound on discontinuation, supporting continuous or cycled use.

Ipamorelin has not been tested alongside tesamorelin in a controlled trial. Every protocol recommendation below should be read with that gap clearly in mind.

Mechanism of Action: How Each Peptide Works

Tesamorelin (Egrifta)

Tesamorelin is a 44-amino-acid GHRH(1-44) analog stabilized with a trans-3-hexenoic acid group that protects the N-terminus from dipeptidyl peptidase IV (DPP-IV) cleavage, extending plasma half-life to roughly 26 minutes vs. The endogenous GHRH's 7 minutes. After subcutaneous injection, it produces a physiologic GH pulse that rises within 15 to 30 minutes and returns to baseline within 90 to 120 minutes, closely matching the natural ultradian GH rhythm. [4]

The FDA approved tesamorelin in November 2010 (NDA 022505) specifically for reducing excess abdominal fat in HIV-infected patients. Off-label use in non-HIV populations is practiced by some clinicians but lacks the same RCT evidence base. [5]

Ipamorelin

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂). Its selectivity is the reason many practitioners choose it over older secretagogues: at therapeutic doses it raises GH and, downstream, IGF-1, without meaningfully elevating cortisol, prolactin, or ACTH. [6] That selectivity profile was demonstrated in a 1998 dose-finding study in conscious male rats, which remains one of the most frequently cited mechanistic references for the compound.

Ipamorelin does not have FDA approval for any indication in humans. It is investigational. That classification matters for informed-consent discussions and compounding pharmacy access.

Rationale for Stacking: Additive GH Pulse Architecture

A single GHRH injection produces a GH pulse. A single GHRP injection produces a GH pulse. Administering both simultaneously within a narrow window creates a substantially larger pulse by activating both the accelerator (GHRH-R) and the release of somatostatin inhibition (GHSR-1a) at the same moment. [2]

The Somatostatin-Suppression Angle

Somatostatin, released from hypothalamic neurons, is the primary brake on pituitary GH secretion. GHRH analogs do not suppress somatostatin; they simply stimulate GH release when somatostatin tone is low. Ipamorelin, acting partly through ghrelin receptor signaling in the hypothalamus, measurably reduces somatostatin release. [7] Giving both peptides together means the GHRH stimulus arrives at somatotrophs whose somatostatin brake has been partially released, allowing a larger GH output.

Pulse Amplitude vs. Pulse Frequency

Tesamorelin's once-daily dosing mirrors physiologic GH pulsatility by triggering one large daily pulse. Adding ipamorelin 2 to 3 times daily can increase pulse frequency at the cost of somewhat blunting receptor sensitivity over time. Practitioners who prioritize the IGLOO-like visceral fat profile typically keep tesamorelin once daily and add ipamorelin once (in the evening, before sleep, when endogenous GH secretion naturally peaks) to avoid over-stimulation. [8]

Complete Stack Protocol

The protocol below synthesizes tesamorelin's FDA-labeling data, the IGLOO study design, published pharmacokinetic data on ipamorelin, and practitioner-reported dosing frameworks. No RCT has tested this exact combination in humans.

Baseline Labs Before Starting

Order the following before the first injection: fasting glucose, HbA1c, insulin, IGF-1, comprehensive metabolic panel, lipid panel, CBC, and (in men over 40) PSA. Pre-existing diabetes or IGF-1 above the age-adjusted upper reference range are relative contraindications requiring physician review before proceeding.

HealthRX Ipamorelin + Tesamorelin Protocol Framework

| Parameter | Tesamorelin (Egrifta) | Ipamorelin | |---|---|---| | Dose | 2 mg | 200 to 300 mcg | | Frequency | Once daily | Once daily (evening) or twice daily (AM + evening) | | Injection route | Subcutaneous, abdomen | Subcutaneous, abdomen | | Timing pre-dose | No food 2 h before | No food 2 h before | | Cycle length | 12 to 26 weeks | Same as tesamorelin cycle | | Off-period | 8 to 12 weeks | 8 to 12 weeks | | IGF-1 check | Week 4 and every 8 weeks | Same schedule |

Dosing Details

Tesamorelin 2 mg once daily is the Phase III-validated dose. The vial arrives as lyophilized powder and requires reconstitution with the supplied sterile water. Inject subcutaneously into the periumbilical region of the abdomen, rotating sites at least 2 cm from the previous injection. Clinical onset for VAT reduction is measurable at 8 weeks by DXA or CT, with peak effect around 26 weeks. [3]

Ipamorelin 200 to 300 mcg once or twice daily. Most practitioners start at 200 mcg once daily, administered 30 to 60 minutes before sleep to align with the nocturnal GH surge. If IGF-1 at week 4 remains in the lower third of the reference range and the patient is tolerating the protocol well, a second 200 mcg dose in the morning (at least 90 minutes after waking and before eating) may be added. Doses above 300 mcg per injection have not shown proportionally greater IGF-1 responses in available data, so higher doses are not recommended. [6]

Timing the Injections Together

Both peptides should be injected within a 5-minute window to capitalize on the simultaneous receptor activation described above. Drawing them into separate syringes and injecting sequentially into different abdominal quadrants is the safest approach. Do not mix tesamorelin and ipamorelin in the same syringe; there are no stability data supporting co-formulation, and the manufacturer's reconstitution instructions for Egrifta specify only the supplied diluent. [5]

Cycle Structure

A 26-week cycle mirrors the IGLOO trial duration and reflects the longest continuous tesamorelin exposure with strong safety data. After 26 weeks, a structured 8-to-12-week off-period allows the hypothalamic-pituitary axis to re-establish baseline sensitivity. Continuing without a break may blunt the GH response as receptor down-regulation accumulates. Some practitioners prefer a 12-week on / 6-week off rotating pattern for year-round maintenance; either approach is observational, not RCT-validated.

Expected Outcomes and What the Evidence Actually Covers

Body Composition

The strongest evidence is for tesamorelin's VAT reduction. In the pooled IGLOO analysis, the 18% mean VAT reduction translated to a statistically significant improvement in trunk-to-limb fat ratio; total body weight changed minimally, and lean mass increased modestly (0.5 to 1.0 kg) at 26 weeks. [3] The contribution of ipamorelin to body composition in this specific combination is unknown; ipamorelin-only human data are limited to case series and small open-label reports.

IGF-1 Response

Tesamorelin raised IGF-1 by a mean of 81 ng/mL from a baseline of roughly 150 ng/mL in the IGLOO trials. [3] Adding a GHRP may raise IGF-1 further. Practitioners should target IGF-1 in the upper quartile of the age-adjusted reference range, not above the range. IGF-1 above the reference range is associated with potential adverse mitogenic signaling, and the FDA label for tesamorelin cautions that the drug should be discontinued if IGF-1 rises above 3 standard deviations above the mean. [5]

Cognition and Sleep Quality

Endogenous GH and IGF-1 influence slow-wave sleep architecture. Patients and practitioners frequently report improved sleep depth and faster sleep onset with GH secretagogue regimens. These reports are consistent with the known role of GH in sleep regulation but have not been validated in RCTs for either ipamorelin or this combination. [8]

Glucose and Insulin Sensitivity

Both compounds can impair glucose homeostasis through GH's insulin-antagonist effects. In the IGLOO trials, fasting glucose rose by a mean of 3 mg/dL and insulin sensitivity (HOMA-IR) worsened modestly, though clinically overt diabetes incidence did not differ significantly from placebo at 26 weeks. [3] Adding ipamorelin may increase this risk incrementally. Patients with pre-diabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) should have fasting glucose checked monthly.

Safety Profile and Contraindications

Known Adverse Effects of Tesamorelin

The tesamorelin FDA label (revised 2023) lists the following most common adverse reactions (incidence >5% and exceeding placebo): injection-site reactions (8.9%), arthralgia (6.5%), pain in extremity (6.0%), peripheral edema (5.7%), and myalgia (5.3%). [5] Fluid retention is a class effect of GH stimulation and typically resolves within the first 4 weeks as the body equilibrates.

Ipamorelin-Specific Considerations

Ipamorelin's published tolerability data come largely from preclinical work and small human pharmacokinetic studies. The compound's selectivity for the ghrelin receptor (GHSR-1a) over corticotropin and prolactin receptors means cortisol and prolactin spikes are less likely than with first-generation GHRPs like GHRP-6. [6] Headache and transient flushing are the most frequently reported patient-reported adverse events in practitioner observational series, typically occurring within 20 minutes of injection and resolving spontaneously.

Absolute Contraindications

Do not use tesamorelin or ipamorelin in active malignancy, intracranial hypertension, or pregnancy. The tesamorelin label carries a specific contraindication for patients with active malignancy and for those with disrupted hypothalamic-pituitary axis from tumors, hypophysectomy, or radiation therapy. [5] Pediatric use is also contraindicated; open epiphyses present a risk of accelerated bone age. Patients with a history of pituitary adenoma should be evaluated by endocrinology before any GH secretagogue use.

Drug Interactions

Tesamorelin may reduce the plasma concentration of drugs metabolized by CYP3A4 (e.g., certain protease inhibitors) because GH itself can modulate CYP enzyme expression. Clinicians managing HIV-infected patients on antiretroviral therapy should review the full interaction table in the Egrifta prescribing information. [5] Ipamorelin lacks formal drug interaction studies, but the same CYP3A4 caveat may apply given the shared downstream GH pathway.

Monitoring Schedule

Structured monitoring is what separates a thoughtful protocol from an informal experiment. The schedule below is adapted from the tesamorelin REMS program recommendations and standard endocrinology practice for GH axis interventions.

Week 0 (baseline): IGF-1, fasting glucose, HbA1c, insulin, comprehensive metabolic panel, lipid panel, CBC.

Week 4: IGF-1, fasting glucose. Adjust ipamorelin dose up to 300 mcg if IGF-1 is below target and tolerability is good. Reduce or hold tesamorelin if fasting glucose exceeds 126 mg/dL on two occasions.

Week 8 and Week 16: IGF-1, fasting glucose, comprehensive metabolic panel. Evaluate body composition by DXA or waist circumference if DXA is not available.

Week 26 (end of cycle): Full baseline panel plus body composition assessment. Compare IGF-1, VAT proxy, and fasting glucose to baseline values. Allow 8 to 12 weeks off before restarting.

The Endocrine Society's 2011 Clinical Practice Guideline on Adult Growth Hormone Deficiency states: "We recommend against treatment of patients with active malignancy, evidence of tumor recurrence or progression on imaging, and in patients with diabetic retinopathy." [9] That guidance applies by extension to any GH-stimulating regimen.

Who Is (and Who Is Not) a Candidate

Likely Candidates

Adults with documented HIV-associated lipodystrophy meet the FDA label for tesamorelin and are the most evidence-supported group. Off-label, practitioners consider this stack for adults 35 and older with confirmed age-related GH decline (low-normal IGF-1, impaired sleep, increased VAT) who have exhausted lifestyle interventions and have no active malignancy, diabetes, or pituitary pathology.

Poor Candidates

Individuals with IGF-1 already in the upper quartile of the reference range at baseline derive little incremental benefit and carry higher risk. Patients with type 2 diabetes or insulin resistance should approach GH-stimulating protocols with significant caution given GH's established insulin-antagonist effects. [10] Patients on growth-hormone replacement (recombinant hGH injection) should not add secretagogues without endocrinology oversight, as the combined IGF-1 elevation may become supraphysiologic.

Evidence Quality Summary

The table below is an honest accounting of what is and is not known about this combination.

| Claim | Evidence Level | Primary Source | |---|---|---| | Tesamorelin reduces VAT by ~18% at 26 weeks | Phase III RCT (IGLOO, N=816) | Falutz et al., NEJM 2007 [3] | | Tesamorelin raises IGF-1 by ~80 ng/mL | Phase III RCT | Falutz et al., NEJM 2007 [3] | | GHRH + GHRP produces supra-additive GH response | Animal + human pharmacokinetic studies | Bowers et al., J Clin Endocrinol Metab 1990 [2] | | Ipamorelin is selective for GHSR-1a over ACTH/prolactin receptors | Preclinical (rat) pharmacology | Raun et al., Eur J Endocrinol 1998 [6] | | Ipamorelin + tesamorelin stack outcomes in humans | No RCT data; practitioner observational | N/A |